Thomas A. Ciulla, MD, MBA, FASRS

Thomas Ciulla, MD, MBA has held numerous leadership roles in publicly-traded biotech companies, including Viridian Therapeutics where he is currently Chief Medical Officer, Clearside Bio (leading to FDA approval of Xipere), Spark Therapeutics (leading to FDA approval of Luxturna gene therapy) and Ophthotech/Iveric. Before launching his executive management career, Dr. Ciulla co-directed the retina service and ocular angiogenesis research lab at Indiana University School of Medicine, the largest U.S. med school. He remains a volunteer Clinical Professor at the university and serves on the Board of Directors of Midwest Eye Institute. He is an active member of the American Society of Gene and Cell Therapy, Association for Research in Vision and Ophthalmology, Macula Society, Retina Society, American Society of Retina Specialists, and the American Academy of Ophthalmology. Dr. Ciulla has held numerous leadership roles in clinical research, including principal investigator, medical monitor, and member of scientific advisory, data safety monitoring or writing committees in over 100 national clinical trials. He has served on journal editorial boards, edited several textbooks, and co-authored more than 300 publications. Dr. Ciulla graduated from Harvard College and UCSF School of Medicine, followed by an internship and residency at Harvard Medical School and a fellowship at Tufts Medical School. He also earned an M.B.A. from Indiana University’s Kelley School of Business, specializing in the business of medicine.